Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:[2]
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:13
  • preuzimanja u poslednjih 30 dana:5
članak: 10 od 62  
Back povratak na rezultate
Hospital Pharmacology - International Multidisciplinary Journal
2016, vol. 3, br. 3, str. 422-434
jezik rada: engleski
vrsta rada: originalan članak
objavljeno: 13/01/2017
doi: 10.5937/hpimj1603422P
Creative Commons License 4.0
Trendovi prometa lekova 'siročića' u Srbiji - analiza 8 godina tržišta lekova 'siročića' u Srbiji
aUniverzitet u Kragujevcu, Medicinski fakultet
bDepartment of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria + Institute for rare diseases, Plovdiv, Bulgaria

e-adresa: anapejcic201502@yahoo.com

Sažetak

Uvod/Cilj: Lekovi 'siročići' su medicinski proizvodi namenjeni za lečenje životno ugrožavajućih ili hronično onesposobljavajućih bolesti koje se javljaju kod malog broja bolesnika. Cilj ovog rada bio je da pruži uvid u trendove prometa lekova 'siročića' u Srbiji. Materijal i metode: Kao izvor podataka o prometu lekova 'siročića' korišćene su publikacije 'Promet i potrošnja lekova za upotrebu u humanoj medicini u Republici Srbiji' Agencije za lekove i medicinska sredstva Srbije (ALIMS) za period od 2006. do 2013. godine. U analizu su uključeni lekovi koji su imali aktivan status lekova 'siročića' i aktivnu dozvolu za promet na tržištu Evropske Unije tokom posmatranog perioda. Za analizu podataka korišćene su metode deskriptivne statistike i opservacija hronoloških trendova. Rezultati: U analiziranim publikacijama identifikovano je 12 lekova 'siročića'. Promet lekova 'siročića' i udeo lekova 'siročića' u ukupnom prometu lekova za humanu upotrebu konstantno su se povećavali od 2006. do 2010. godine. Tokom 2011. i 2012. godine počeli su blago da opadaju, a zatim je u 2013. godini zabeleženo skoro trostruko smanjenje u odnosu na 2012. godinu. Udeo lekova 'siročića' u ukupnom prometu lekova za humanu upotrebu nije prešao 1% ukupnog prometa lekova za humanu upotrebu tokom posmatranog osmogodišnjeg perioda. Najveći udeo u prometu lekova 'siročića' imao je imatinib (87,36%-97,13%).Nagli pad u prometu lekova 'siročića' u 2013. godini mogao bi biti objašnjen činjenicom da je tokom 2012. godine imatinib povučen iz Registra lekova 'siročića' Evropske Unije. Zaključak: Promet lekova 'siročića' od 2006. do 2013. godine bio je skoro neznatan u odnosu na ukupan promet lekova za humanu upotrebu. U poslednjoj posmatranoj godini primećen je značajan pad prometa, pre svega zbog činjenice da imatinib u toj godini nije više pripadao grupi lekova 'siročića'. Da bi se istražili dugoročni trendovi potreban je veći vremenski horizont.

Ključne reči

lekovi 'siročići'; farmaceutski troškovi; Srbija; retka bolest; potrošnja; promet

Reference

*** (2009) Council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02). Official Journal of the European Union, C151:7-10, 2016 Aug 12, http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF
*** (2000) Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Offic J Europ Communities, L18, 1-5, 2016 Jul 31, http://ec.europa.eu/health/files/eudralex/vol-1/ reg_2000_141/reg_2000_141_en.pdf
*** (2010-2012) Law on medicines and medical devices. Official Gazette of the Republic of Serbia, 30/2010 and 107/2012, 2016 Aug 05, http://www.alims.gov.rs/ciril/files/2012/11/zakon-30-2010-107-2012.doc
*** (2014-2015) Regulations of conditions for the import of medicines and medical devices without marketing authorization. Official Gazette of the Republic of Serbia, 02/2014, 14/2014, 111/2014 and 52/2015, 2016 Aug 07, http://www.rfzo.rs/download/pravilnici/mz/Pravilnik_uvoz_bezregistra-19062015.pdf
*** (2014-2015) Regulations of the conditions, criteria, mode and procedure for placing a drug on the List of reimbursed drugs, amendments to the List of reimbursed drugs, or for removal of the drug from the list of reimbursed drugs. Official Gazette of the Republic of Serbia, 41/2014, 125/2014, 48/2015, 2016 Aug 07, http://www.rfzo.rs/download/pravilnici/lekovi/Pravilnik_uslovi_ListaLekova-10062015.pdf
*** (2015-2016) Regulation of the List of the reimbursed drugs which are covered by compulsory health insurance. Official Gazette of the Republic of Serbia, 65/2015, 71/2015, 104/2015, 24/2016, 57/2016, 61/2016 and 78/2016, 2016 Aug 07, http://rfzo.rs/download/pravilnici/lekovi/ Pravilnik_o_listi_lekova27062016.pdf
*** (2005-2016) Law on health insurance. Official Gazette of the Republic of Serbia, 107/2005, 109/2005, 30/2010, 57/2011, 110/2012, 119/2012, 99/2014, 123/2014, 126/2014, 106/2015 and 10/2016, 2016 Aug 07, http://www.rfzo.rs/download/zakoni/Zakon_o_zdrav_osiguranju01042016.pdf
*** (2015) Budget of the Ministry of health of the Republic of Serbia for 2015. 2016 Aug 07, http://www.zdravlje.gov.rs/downloads/2015/Februar/Februar2015Budzet2015SluzbeniGlasnik.pdf
*** Budget of the Ministry of health of the Republic of Serbia for 2016. 2016 Aug 07, http://www.zdravlje.gov.rs/downloads/2016/April/April2016Budzet2016.pdf
*** (2008) Preparation of Professional Publications of the Agency. Report on turnover and consumption of pharmaceuticals in the Republic of Serbia in 2007. Belgrade: Medicines and Medical Devices Agency of Serbia, [cited 2016Jul 27]. Available from: http://www.alims.gov.rs/ciril/files/2012/09/03- Promet-i-potrosnja-lekova-2007.pdf
*** (2009) Preparation of Professional Publications of the Agency. Report on turnover and consumption of pharmaceuticals in the Republic of Serbia in 2008. Belgrade: Medicines and Medical Devices Agency of Serbia, [cited 2016Jul 27]. Available from: http://www.alims.gov.rs/ciril/files/2012/09/04- Promet-i-potrosnja-lekova-2008.pdf
*** (2010) Preparation of Professional Publications of the Agency. Report on turnover and consumption of pharmaceuticals in the Republic of Serbia in 2009. Belgrade: Medicines and Medical Devices Agency of Serbia, [cited 2016Jul 27]. Available from: http://www.alims.gov.rs/ciril/files/2012/09/05-Promet-i-potrosnja-lekova-2009.pdf
*** (2011) Preparation of Professional Publications of the Agency. Report on turnover and consumption of pharmaceuticals in the Republic of Serbia in 2010. Belgrade: Medicines and Medical Devices Agency of Serbia, [cited 2016Jul 27]. Available from: http://www.alims.gov.rs/ciril/files/2013/02/ Promet_2010.pdf
*** (2012) Preparation of Professional Publications of the Agency. Report on turnover and consumption of pharmaceuticals in the Republic of Serbia in 2011. Belgrade: Medicines and Medical Devices Agency of Serbia, [cited 2016Jul 27]. Available from: http://www.alims.gov.rs/ciril/fi les/2012/06/092_13_02239_2013_5_001_1_pdf.pdf
*** Publications. Belgrade: Medicines and Medical Devices Agency of Serbia, http://www.alims.gov.rs/ciril/o-agenciji/publikacije/
*** (2013) Preparation of Professional Publications of the Agency. Report on turnover and consumption of pharmaceuticals in the Republic of Serbia in 2012. Belgrade: Medicines and Medical Devices Agency of Serbia, [cited 2016Jul 27]. Available from: http://www.alims.gov.rs/ciril/fi les/2014/09/PROMET_javnost-2012.pdf
*** (2014) Preparation of Professional Publications of the Agency. Report on turnover and consumption of pharmaceuticals in the Republic of Serbia in 2013. Belgrade: Medicines and Medical Devices Agency of Serbia, [cited 2016Jul 27]. Available from: http://www.alims.gov.rs/ciril/files/2016/03/ PPL_2013.pdf
*** (2016) Lists of medicinal products for rare diseases in Europe. u: Orphanet Report Series, Orphan Drugs collection, 27 July 2016, http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf
*** (2007) Preparation of Professional Publications of the Agency. Report on turnover and consumption of pharmaceuticals in the Republic of Serbia in 2006. Belgrade: Medicines and Medical Devices Agency of Serbia, [cited 2016Jul 27]. Available from: http://www.alims.gov.rs/ciril/files/2012/09/02- Promet-i-potrosnja-lekova-2006.pdf
Aronson, J.K. (2006) Rare diseases and orphan drugs. British journal of clinical pharmacology, 61(3): 243-5
Chiang, P., Yang, W. (2016) The expenditure and reimbursement of orphan drug in taiwan: challenges and opportunities. Value in Health, 19(3): A255
Cohen, J.P., Felix, A. (2014) Are payers treating orphan drugs differently?. Journal of Market Access & Health Policy, 2(1): 23513
de Varax, A., Letellier, M., Börtlein, G. (2004) Study of orphan drugs. Alcimed, 2016, Aug 02, http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf
Denis, A., Mergaert, L., Fostier, C., Cleemput, I., Simoens, S. (2010) Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe. Applied Health Economics and Health Policy, 8(5): 343-350
Denis, A., Mergaert, L., Fostier, C., Cleemput, I., Simoens, S. (2010) Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. Journal of Medical Economics, 13(2): 295-301
Divino, V., Dekoven, M., Wang, W., Kleinrock, M., Harvey, R.D., Wade, R.L., Kaura, S. (2014) The Budget Impact of Orphan Drugs in the U. S. A 2007-2013 MIDAS Sales Data Analysis. Blood, 124(21); 736
Divino, V., DeKoven, M., Kleinrock, M., Wade, R.L., Kim, T., Kaura, S. (2016) Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis. Orphanet Journal of Rare Diseases, 11(1):68
European Medicines Agency Find medicine section. 2016 Jul 28, http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp
Gammie, T., Lu, C.Y., Babar, Z.U. (2015) Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLOS ONE, 10(10): e0140002
Gong, S., Wang, Y., Pan, X., Zhang, L., Huang, R., Chen, X., Hu, J., Xu, Y., Jin, S. (2016) The availability and affordability of orphan drugs for rare diseases in China. Orphanet Journal of Rare Diseases, 11(1): 20
Heemstra, H.E., de Vrueh, R.L., van Weely, S., Büller, H.A., Leufkens, H.G. M. (2008) Predictors of orphan drug approval in the European Union. European Journal of Clinical Pharmacology, 64(5): 545-552
Hutchings, A., Schey, C., Dutton, R., Achana, F., Antonov, K. (2014) Estimating the budget impact of orphan drugs in Sweden and France 2013–2020. Orphanet Journal of Rare Diseases, 9(1): 22
Iskrov, G., Miteva-Katrandzhieva, T., Stefanov, R. (2012) Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria. Health Policy, 108(1): 10-18
Jakovljevic, M.B. (2014) Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia. Health economics and therapeutic pathways, 15(1): 27
Jakovljevic, M.B., Nakazono, S., Ogura, S. (2014) Contemporary generic market in Japan - key conditions to successful evolution. Expert review of pharmacoeconomics & outcomes research, 14(2): 181-94
Jakovljevic, M.B. (2013) Resource allocation strategies in Southeastern European health policy. European journal of health economics, 14(2): 153-9
Jakovljevic, M.B., Djordjevic, N., Jurisevic, M., Jankovic, S. (2015) Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. Expert review of pharmacoeconomics & outcomes research, 15(3): 521-30
Jakovljević, M., Lazarević, M., Milovanović, O., Kanjevac, T. (2016) The New and Old Europe: East-West Split in Pharmaceutical Spending. Front Pharmacol, 7: 18
Jakovljević, M., Ogura, S. (2016) Health Economics at the Crossroads of Centuries - From the Past to the Future. Front Public Health, 4: 115
Jakovljević, M., Getzen, T.E. (2016) Growth of Global Health Spending Share in Low and Middle Income Countries. Front Pharmacol, 7: 21
Jakovljević, M., Souliotis, K. (2016) Pharmaceutical expenditure changes in Serbia and Greece during the global economic recession. South Eastern European Journal of Public Health, 5(1)
Jakovljević, M.B. (2014) Health expenditure dynamics in Serbia 1995-2012. Hospital Pharmacology - International Multidisciplinary Journal, vol. 1, br. 3, str. 180-183
Jakovljević, M., Jovanović, M., Lazić, Z., Jakovljević, V., Đukić, A., Velicković, R., Antunović, M. (2011) Current efforts and proposals to reduce healthcare costs in Serbia. Serbian Journal of Experimental and Clinical Research, vol. 12, br. 4, str. 161-163
Kanters, T.A., Steenhoek, A., Hakkaart, L. (2014) Orphan drugs expenditure in the Netherlands in the period 2006–2012. Orphanet Journal of Rare Diseases, 9(1): 154
Koçkaya, G., Wertheimer, A.I., Kilic, P., Tanyeri, P., Vural, İ. M., Akbulat, A., Artiran, G., Kerman, S. (2014) An Overview of the Orphan Medicines Market in Turkey. Value in Health Regional Issues, 4: 47-52
Kontoghiorghe, C.N. (2014) World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World Journal of Methodology, 4(3): 163
Krajnović, D., Arsić, J., Jocić, D., Georgiev-Milošević, A., Tasić, L., Marinković, V. (2013) Evaluation of pharmacists' knowledge and attitudes regarding rare diseases and orphan drugs. Acta medica Medianae, vol. 52, br. 2, str. 23-32
Logviss, K., Krievins, D., Purvina, S. (2016) Impact of orphan drugs on Latvian budget. Orphanet journal of rare diseases, 11(1): 59
Meekings, K.N., Williams, C.S.M., Arrowsmith, J.E. (2012) Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discovery Today, 17(13-14): 660-664
National Bank of Serbia Exchange rate lists for a specific period. 2016 Jul 29, http://www.nbs.rs/export/sites/default/internet/english/scripts/kl_period.html
National Organization for Rare Diseases of Serbia About national organization for rare diseases of Serbia. 2016 Aug 05, http://www.norbs.rs/o-norbs-u/
Orofino, J., Soto, J., Casado, M.A., Oyagüez, I. (2010) Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007. Applied Health Economics and Health Policy, 8(5): 301-315
Pavlović, N., Stanimirov, B., Stojančević, M., Kusturica, M. P., orbin-Kon S, G., Mikov, M. (2013) Low availability of orphan medicines in Serbia. Value in Health, 16(3): A123-A124
Pavlović, N., Stanimirov, B., Stojančević, M., Paut-Kusturica, M., Stoimenova, A., Goločorbin-Kon, S., Mikov, M. (2012) An Insight on Differences in Availability and Reimbursement of Orphan Medicines Among Serbia, Bulgaria and Sweden. Biotechnology & Biotechnological Equipment, 26(5): 3236-3241
Picavet, E., Annemans, L., Cleemput, I., Cassiman, D., Simoens, S. (2012) Market uptake of orphan drugs - a European analysis. Journal of Clinical Pharmacy and Therapeutics, 37(6): 664-667
Picavet, E., Dooms, M., Cassiman, D., Simoens, S. (2011) Drugs for rare diseases: influence of orphan designation status on price. Applied health economics and health policy, 9(4): 275-9
Rodwell, C., Aymé, S., ur. (2014) Report on the state of the art of rare disease activities in Europe. July 2014, http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivitiesRS.pdf, 2016 Aug 05
Schey, C., Milanova, T., Hutchings, A. (2011) Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. Orphanet Journal of Rare Diseases, 6(1): 62
Simoens, S. (2011) Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet Journal of Rare Diseases, 6(1): 42
Song, P., Gao, J., Inagaki, Y., Kokudo, N., Tang, W. (2012) Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable & rare diseases research, 1(1): 3-9
Sujkowska, G., Jagodzinska-Kalinowska, K., Matusewicz, W. (2015) The availability and Expenditure of Orphan Medicines in Poland. Value in Health, 18(3): A304
The National Health Insurance Fund of the Republic of Serbia About National health insurance fund of the Republic of Serbia. 2016 Aug 07, http://www.eng.rfzo.rs/index.php/aboutus
Vocelka, M., Spurna, M., Fuksa, L., Hambalek, J. (2014) Public Expenditure On Authorised Orphan Drugs In the Czech Republic Between 2008 and 2013. Value in Health, 17(7): A526
Wästfelt, M., Fadeel, B., Henter, J. (2006) A journey of hope: lessons learned from studies on rare diseases and orphan drugs. Journal of internal medicine, 260(1): 1-10
Winstone, J., Chadda, S., Ralston, S., Sajosi, P. (2015) Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments. Orphanet Journal of Rare Diseases, 10(1): 139
Wonder, M., Chin, G. (2015) What impact does ‘conventional’ economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005–2012). Expert Review of Pharmacoeconomics & Outcomes Research, 15(5): 843-850
Zlatareva, A., Lakic, D., Kamusheva, M., Spaskov, D., Momekov, G., Petrova, G. (2013) Analysis of Access to Orphan Drugs in Five Neighboring European Countries - Bulgaria, Greece, Macedonia, Romania and Serbia. World Journal of Pharmacy and Pharmaceutical Sciences, 2(6); 4415-34